Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: Elagolix
  • Price: $450.0/100mg $800.0/250mg $1600.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

834153-87-6

834153-87-6 structure
834153-87-6 structure
  • Name: elagolix
  • Chemical Name: Elagolix
  • CAS Number: 834153-87-6
  • Molecular Formula: C32H30F5N3O5
  • Molecular Weight: 631.590
  • Catalog: API Hormone and endocrine-regulating drugs Gonadotropin
  • Create Date: 2018-07-08 11:23:38
  • Modify Date: 2024-01-04 15:47:51
  • Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.

Name Elagolix
Synonyms 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid
Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-
Elagolix
Description Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.
Related Catalog
References

[1]. Carr B, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-1351.

Density 1.4±0.1 g/cm3
Boiling Point 728.6±70.0 °C at 760 mmHg
Molecular Formula C32H30F5N3O5
Molecular Weight 631.590
Flash Point 394.5±35.7 °C
Exact Mass 631.210571
PSA 102.56000
LogP 7.20
Vapour Pressure 0.0±2.5 mmHg at 25°C
Index of Refraction 1.567
Storage condition 2-8℃

~91%

834153-87-6 structure

834153-87-6

Literature: NEUROCRINE BIOSCIENCES, INC. Patent: WO2009/62087 A1, 2009 ; Location in patent: Page/Page column 17, 18 ; WO 2009/062087 A1

~%

834153-87-6 structure

834153-87-6

Literature: Journal of Medicinal Chemistry, , vol. 51, # 23 p. 7478 - 7485